Palbociclib Isethionate [827022-33-3]
P0344
Estimated Purity≥98%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NamePalbociclib Isethionate [827022-33-3]
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥98%
- FormatWater 10 mg/mL warmed (17.43 mM); DMSO Insoluble; Ethanol Insoluble
- Scientific DescriptionCDK4/6 inhibitor.; PD0332991-0054, PF00080665-73
- Storage Instruction-20°C
- UNSPSC12352200
References
- Vaughn DJ, Hwang W, Lal P, et al. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer. 2014 Dec 18. [Epub ahead of print]. PMID: 25522918. DiRocco DP, Bisi J, Roberts P, et al. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. Am J Physiol Renal Physiol. 2014 Feb 15;306(4):F379-88. PMID: 24338822. Barton KL, Misuraca K, Cordero F, et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One. 2013 Oct 2;8(10):e77639. PMID: 24098593. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. PMID: 15542782.